Present clinical practice of breast cancer radiotherapy in Italy: a nationwide survey by the Italian Society of Radiotherapy and Clinical Oncology (AIRO) Breast Group

Hypofractionated radiation therapy for breast cancer: Preferences amongst radiation oncologists in Europe – Results from an international survey

“…Other researchers have also described the infrequent use of HF-WBI and various concerns regarding higher daily fractionation dose, even after the publication of key clinical studies. The reported HF-WBI utilisation rates vary across the globe, from 34.5% to 95%, [20,[26][27][28][29], reflecting geographical and also time variations, and the most common regimes are 40.05-42.56 Gy, delivered in 15-16 fractions [27][28][29]. Younger age [27][28][29][30], breast laterality [28,30], breast volume [30], radiation plan (in)homogeneity [27], receipt of adjuvant chemotherapy [27,28,30], BC stage [27] and triple-negative biology [28] were all reported to lead to lower HF-WBI utilisation.…”

“…The reported HF-WBI utilisation rates vary across the globe, from 34.5% to 95%, [20,[26][27][28][29], reflecting geographical and also time variations, and the most common regimes are 40.05-42.56 Gy, delivered in 15-16 fractions [27][28][29]. Younger age [27][28][29][30], breast laterality [28,30], breast volume [30], radiation plan (in)homogeneity [27], receipt of adjuvant chemotherapy [27,28,30], BC stage [27] and triple-negative biology [28] were all reported to lead to lower HF-WBI utilisation. The use of HFRT schedules is likewise not universally adopted in patients with BC who require PMRT or RNI due to concerns regarding acute and late toxicities, especially with respect to lymphedema, shoulder symptoms and peripheral neuropathy [29,31].…”

Established and Validated Novel Nomogram for Predicting Prognosis of Post-Mastectomy pN0-1 Breast Cancer without Adjuvant Radiotherapy

“…3,4 However, the optimal adjuvant treatment for this patient population (pN0-1) remains to be clearly determined. 5 Recently, two large phase III randomized controlled trials, National Cancer Institute of Canada Clinical Trials Group MA20 6 and the European Organization for Research and Treatment of Cancer (EORTC) 22,922-10,925, 7 reported the 10year follow-up results, and both of them indicated that there was an improved disease-free survival with the addition of regional lymph node irradiation to wholebreast RT for early-stage breast cancers, which suggested that adjuvant radiotherapy in early-stage breast cancer not only decreased the risk of local regional recurrence (LRR), but also the risk of developing distant metastasis (DM). However, only 24% of patients in the EORTC trial were treated with mastectomy, and all of enrolled patients in MA20 were treated with lumpectomy.…”

Radiation Oncologists’ Approach to Internal Mammary Lymph Node Radiotherapy in Breast Cancer: The Turkish Society for Radiation Oncology Breast Cancer Study Group (TROD 06-005 Survey Study)

“…19 The study by Gregucci et al showed that the complete pathological response to NAC is a predictive prognostic factor, and it influences the indication to the chest wall, and the ipsilateral lymph node irradiation after NAC is the extension of the disease at diagnosis (cT3-T4 and/or cN2-N3). 20 A recently published review also demonstrated that adjuvant radiotherapy including RNI after NAC should be based on pre-treatment investigations. 21 The selection of radiotherapy techniques is essential to decrease the complications associated with IMNRT.…”